Buy 2, get 1 free
Tesa
$180.00$108.00Save 40%
40% off sitewide · no code needed
QUANTITY PRICING
- Ships within 24 hours, with tracking. Free standard shipping on invoices over $175. 2-Day and Overnight options at invoicing.
- Free shipment protection: lost, stolen or damaged shipments are replaced.
We accept Visa, Amex, Apple Pay and Google Pay.
COMPOUND RESEARCH
How it is studied
Secretagogue peptide
Tesamorelin is a synthetic analog of human growth-hormone-releasing hormone, modified at the N-terminus with a trans-3-hexenoyl group that improves stability against enzymatic degradation. It is a standard reference GHRH agonist in adipose-tissue and GH-axis research. Research use only.
GHRH receptor agonism
Binds the GHRH receptor to stimulate endogenous growth-hormone release in pituitary models.
Visceral adipose models
Widely studied in visceral adipose tissue endpoints. Not a human efficacy claim.
Enzymatic stability
The N-terminal modification extends half-life relative to native GHRH(1-44).
COMMONLY RESEARCHED TOGETHER
Related Research Compounds
PROGRAM PRICING FOR YOUR LAB
Volume Pricing for Labs
40% off from 10 units, 50% off from 50. Free 2-day signed delivery.
VERIFIED TEST RESULTS
Every batch, independently verified.
Freedom Diagnostics tested this lot on 7 Jul 2026. These results apply to this lot only.
Results for this lot
- Purity
- 99.87%
- Identity
- Conforms (reference match)
- Content
- 10.57 mg
- Appearance
- White lyophilized powder
All lots on record
MOLECULAR PROFILE
Compound Information
- CAS Number
- 218949-48-5
- Molecular Weight
- 5135.9 g/mol
- Formula
- C221H366N72O67S
IMPORTANT RESEARCH NOTICE
Sold for research and educational purposes only. Not for human, veterinary or food use, and not intended to diagnose, treat, cure or prevent any disease. By purchasing, you confirm you are a qualified researcher and will follow all applicable laws.
Compounds, paperwork and steady supply for your lab, all from one place.
View all compoundsLab notices from On Top Labs
New compounds, fresh lot certificates and lead-time updates.







